| Year |
Citation |
Score |
| 2023 |
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, ... ... Nayar U, et al. A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532. PMID 37141550 DOI: 10.1200/PO.22.00532 |
0.601 |
|
| 2021 |
Qi M, Nayar U, Ludwig LS, Wagle N, Rheinbay E. cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. Bmc Bioinformatics. 22: 611. PMID 34952565 DOI: 10.1186/s12859-021-04529-2 |
0.438 |
|
| 2020 |
Mao P, Cohen O, Kowalski KJ, Kusiel J, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung JH, Freeman SS, Rozenblatt-Rosen O, Miller VA, Piccioni F, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32723837 DOI: 10.1158/1078-0432.Ccr-19-3958 |
0.555 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390 |
0.657 |
|
| 2020 |
Persky NS, Hernandez D, Do Carmo M, Brenan L, Cohen O, Kitajima S, Nayar U, Walker A, Pantel S, Lee Y, Cordova J, Sathappa M, Zhu C, Hayes TK, Ram P, et al. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural & Molecular Biology. 27: 92-104. PMID 31925410 DOI: 10.1038/S41594-019-0358-Z |
0.311 |
|
| 2018 |
Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, et al. Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics. PMID 30531871 DOI: 10.1038/S41588-018-0287-5 |
0.603 |
|
| 2018 |
Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016 |
0.645 |
|
| 2017 |
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, et al. Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of Clinical Investigation. PMID 28504647 DOI: 10.1172/Jci83936 |
0.626 |
|
| 2015 |
Nayar U, Sadek J, Reichel JB, Bunn D, Hernandez-Hopkins D, Barelli P, Sahai M, Totonchy J, Shizuko S, Shoemaker R, Warren D, Elemento O, Kaye K, Cesarman E. Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase Blood. 126: 1812-1812. DOI: 10.1182/Blood.V126.23.1812.1812 |
0.623 |
|
| 2015 |
Nayar U, Reichel J, Sadek J, Hernandez-Hopkins D, Akar G, Zhou H, Sahai MA, Barelli P, Guasparri I, Totonchy J, Hassane D, Sei S, Shoemaker RH, Warren JD, Elemento O, et al. Abstract 4496: Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor Cancer Research. 75: 4496-4496. DOI: 10.1158/1538-7445.Am2015-4496 |
0.545 |
|
| 2013 |
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122: 2837-47. PMID 23943653 DOI: 10.1182/Blood-2013-01-479972 |
0.586 |
|
| 2012 |
Nayar U, Akar G, Shoemaker RH, Sei S, Cesarman E. Identification of a Novel Inhibitor That Selectively Targets NF-κB Activity in KSHV-Infected Lymphoma Cells Blood. 120: 160-160. DOI: 10.1182/Blood.V120.21.160.160 |
0.588 |
|
| 2012 |
Nayar U, Lu P, Vider J, Goldstein RL, Ballon G, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Abstract 4829: A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP Cancer Research. 72: 4829-4829. DOI: 10.1158/1538-7445.Am2012-4829 |
0.61 |
|
| 2010 |
Nayar U, Lu P, Vider J, Cerchietti L, Chiosis G, Wang L, Blasberg R, Cesarman E. Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma Infectious Agents and Cancer. 5. DOI: 10.1186/1750-9378-5-S1-A36 |
0.6 |
|
| Show low-probability matches. |